This protocol applies to patients with advanced or metastatic liposarcoma who present with clinically resectable lung metastases — specifically in the absence of extrapulmonary disease. The timing of metastatic presentation is a key factor in determining the treatment pathway.
For synchronous lung metastases with no extrapulmonary disease, systemic chemotherapy is the standard first-line treatment. Following chemotherapy, surgical resection of residual lung lesions may be considered in selected patients — particularly those in whom a tumour response has been achieved.
DOI: 10.1016/j.annonc.2021.07.006
Advanced/metastatic, clinically resectable STS.
Standard treatment of metachronous (disease-free interval 1 year), resectable lung metastases without extrapulmonary disease is surgery, if complete excision of all lesions is feasible [IV, B].
When lung metastases are synchronous, in the absence of extrapulmonary disease, standard treatment is ChT [III, B].
Surgery for resectable residual lung metastases may be offered as an option after ChT, especially when a tumour response is achieved.
View source ↗